282 related articles for article (PubMed ID: 34340251)
1. Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease.
Svetnik V; Wang TC; Ceesay P; Snyder E; Ceren O; Bliwise D; Budd K; Hutzelmann J; Stevens J; Lines C; Michelson D; Herring WJ
J Sleep Res; 2021 Dec; 30(6):e13328. PubMed ID: 34340251
[TBL] [Abstract][Full Text] [Related]
2. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
Herring WJ; Ceesay P; Snyder E; Bliwise D; Budd K; Hutzelmann J; Stevens J; Lines C; Michelson D
Alzheimers Dement; 2020 Mar; 16(3):541-551. PubMed ID: 31944580
[TBL] [Abstract][Full Text] [Related]
3. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo.
Roehrs T; Withrow D; Koshorek G; Verkler J; Bazan L; Roth T
J Clin Sleep Med; 2020 Mar; 16(3):415-421. PubMed ID: 31992394
[TBL] [Abstract][Full Text] [Related]
4. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
[TBL] [Abstract][Full Text] [Related]
5. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.
Matsumura T; Terada J; Yoshimura C; Koshikawa K; Kinoshita T; Yahaba M; Nagashima K; Sakao S; Tatsumi K
Drug Des Devel Ther; 2019; 13():809-816. PubMed ID: 30880914
[TBL] [Abstract][Full Text] [Related]
6. How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients?
Svetnik V; Snyder ES; Tao P; Roth T; Lines C; Herring WJ
Sleep Med; 2020 Mar; 67():137-146. PubMed ID: 31926466
[TBL] [Abstract][Full Text] [Related]
7. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
[TBL] [Abstract][Full Text] [Related]
8. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
[TBL] [Abstract][Full Text] [Related]
9. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
[TBL] [Abstract][Full Text] [Related]
10. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
11. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.
Sun H; Kennedy WP; Wilbraham D; Lewis N; Calder N; Li X; Ma J; Yee KL; Ermlich S; Mangin E; Lines C; Rosen L; Chodakewitz J; Murphy GM
Sleep; 2013 Feb; 36(2):259-67. PubMed ID: 23372274
[TBL] [Abstract][Full Text] [Related]
12. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
[TBL] [Abstract][Full Text] [Related]
13. Validation of a Consumer Sleep Wearable Device With Actigraphy and Polysomnography in Adolescents Across Sleep Opportunity Manipulations.
Lee XK; Chee NIYN; Ong JL; Teo TB; van Rijn E; Lo JC; Chee MWL
J Clin Sleep Med; 2019 Sep; 15(9):1337-1346. PubMed ID: 31538605
[TBL] [Abstract][Full Text] [Related]
14. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
Sun H; Palcza J; Card D; Gipson A; Rosenberg R; Kryger M; Lines C; Wagner JA; Troyer MD
J Clin Sleep Med; 2016 Jan; 12(1):9-17. PubMed ID: 26194728
[TBL] [Abstract][Full Text] [Related]
15. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
[TBL] [Abstract][Full Text] [Related]
16. Comparison of polysomnography in people with Alzheimer's disease and insomnia versus non-demented elderly people with insomnia.
Tao P; Svetnik V; Bliwise DL; Zammit G; Lines C; Herring WJ
Sleep Med; 2023 Jan; 101():515-521. PubMed ID: 36529106
[TBL] [Abstract][Full Text] [Related]
17. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial.
Zeitzer JM; Joyce DS; McBean A; Quevedo YL; Hernandez B; Holty JE
JAMA Netw Open; 2020 Jun; 3(6):e206614. PubMed ID: 32484552
[TBL] [Abstract][Full Text] [Related]
18. Effects of suvorexant on sleep apnea in patients with heart failure: A protocol of crossover pilot trial.
Shitara J; Kasai T; Akihiro S; Yatsu S; Matsumoto H; Suda S; Ogita M; Yanagisawa N; Fujibayashi K; Nojiri S; Nishizaki Y; Ono N; Suwa S; Daida H
J Cardiol; 2019 Jul; 74(1):90-94. PubMed ID: 30737183
[TBL] [Abstract][Full Text] [Related]
19. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.
Rahman SA; Nathan MD; Wiley A; Crawford S; Cohn AY; Harder JA; Grant LK; Erickson A; Srivastava A; McCormick K; Bertisch SM; Winkelman JW; Joffe H
Sleep; 2022 Mar; 45(3):. PubMed ID: 35022783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
